Quick Takeaways
- Patrick G. Enright has 6 issuer positions tracked on this page.
- Estimated disclosed ownership value: $172,094,301.
- Recent insider filing activity is available below.
- Info
- Significant Ownership
- Insider Ownership
Insider Trading & Ownership of Patrick G. Enright
- Location
- Menlo Park, CA
- Summary
- The estimated net worth of Patrick G. Enright is at least $172,094,301 dollars as of 05 Feb 2026. Patrick G. Enright is the Director of Vera Therapeutics, Inc. and owns shares of Vera Therapeutics, Inc. (VERA) stock worth about $102.61M. Patrick G. Enright is the Director of Zenas BioPharma, Inc. and owns shares of Zenas BioPharma, Inc. (ZBIO) stock worth about $35.07M. Patrick G. Enright is the Director of BioAge Labs, Inc. and owns shares of BioAge Labs, Inc. (BIOA) stock worth about $30.79M. Patrick G. Enright is the Director of Jazz Pharmaceuticals plc and owns shares of Jazz Pharmaceuticals plc (JAZZ) stock worth about $3.62M.
- Signature
- /s/ Michael Greco, Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Patrick G. Enright and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: Vera Therapeutics, Inc. ($102,609,021).
- Past-year value change for that position: +$5,527,296.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Patrick G. Enright
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| VERA | Vera Therapeutics, Inc. | Director | $102,609,021 | +$5,527,296 | +5.7% | 11 Dec 2025 |
| ZBIO | Zenas BioPharma, Inc. | Director | $35,070,702 | +$2,250,027 | +6.9% | 09 Oct 2025 |
| BIOA | BioAge Labs, Inc. | Director | $30,790,602 | 05 Jun 2025 | ||
| JAZZ | Jazz Pharmaceuticals plc | Director | $3,623,976 | 18 Aug 2025 | ||
| APTX | Aptinyx Inc. | Director | 26 May 2022 | |||
| MANE | Veradermics, Inc | Director, 10%+ Owner | 03 Feb 2026 |
Insider Transactions Reported by Patrick G. Enright:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.